| First Author | Capietto AH | Year | 2013 |
| Journal | J Exp Med | Volume | 210 |
| Issue | 11 | Pages | 2257-71 |
| PubMed ID | 24127488 | Mgi Jnum | J:206537 |
| Mgi Id | MGI:5551351 | Doi | 10.1084/jem.20130281 |
| Citation | Capietto AH, et al. (2013) Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med 210(11):2257-71 |
| abstractText | Myeloid-derived suppressor cells (MDSCs) favor tumor promotion, mainly by suppressing antitumor T cell responses in many cancers. Although the mechanism of T cell inhibition is established, the pathways leading to MDSC accumulation in bone marrow and secondary lymphoid organs of tumor-bearing hosts remain unclear. We demonstrate that down-regulation of PLCgamma2 signaling in MDSCs is responsible for their aberrant expansion during tumor progression. PLCgamma2(-/-) MDSCs show stronger immune-suppressive activity against CD8(+) T cells than WT MDSCs and potently promote tumor growth when adoptively transferred into WT mice. Mechanistically, PLCgamma2(-/-) MDSCs display reduced beta-catenin levels, and restoration of beta-catenin expression decreases their expansion and tumor growth. Consistent with a negative role for beta-catenin in MDSCs, its deletion in the myeloid population leads to MDSC accumulation and supports tumor progression, whereas expression of beta-catenin constitutively active reduces MDSC numbers and protects from tumor growth. Further emphasizing the clinical relevance of these findings, MDSCs isolated from pancreatic cancer patients show reduced p-PLCgamma2 and beta-catenin levels compared with healthy controls, similar to tumor-bearing mice. Thus, for the first time, we demonstrate that down-regulation of PLCgamma2-beta-catenin pathway occurs in mice and humans and leads to MDSC-mediated tumor expansion, raising concerns about the efficacy of systemic beta-catenin blockade as anti-cancer therapy. |
